On Monday, Editas Medicine Inc (NASDAQ: EDIT) was -7.94% drop from the session before settling in for the closing price of $1.26. A 52-week range for EDIT has been $1.16 – $11.58.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 135.89% over the past five years. When this article was written, the company’s average yearly earnings per share was at -35.17%. With a float of $81.78 million, this company’s outstanding shares have now reached $82.54 million.
Let’s look at the performance matrix of the company that is accounted for 265 employees. In terms of profitability, gross margin is 90.46%, operating margin of -370.03%, and the pretax margin is -340.96%.
Editas Medicine Inc (EDIT) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Editas Medicine Inc stocks. The insider ownership of Editas Medicine Inc is 0.93%, while institutional ownership is 67.79%. The most recent insider transaction that took place on Dec 03 ’24, was worth 3,361. In this transaction CEO of this company sold 1,618 shares at a rate of $2.08, taking the stock ownership to the 312,106 shares. Before that another transaction happened on Dec 03 ’24, when Company’s EVP, CHIEF MEDICAL OFFICER sold 541 for $2.08, making the entire transaction worth $1,124. This insider now owns 133,354 shares in total.
Editas Medicine Inc (EDIT) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.56 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -35.17% per share during the next fiscal year.
Editas Medicine Inc (NASDAQ: EDIT) Trading Performance Indicators
You can see what Editas Medicine Inc (EDIT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.75. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.55.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.56, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -1.51 in one year’s time.
Technical Analysis of Editas Medicine Inc (EDIT)
Editas Medicine Inc (NASDAQ: EDIT) saw its 5-day average volume 3.24 million, a positive change from its year-to-date volume of 3.08 million. As of the previous 9 days, the stock’s Stochastic %D was 36.76%. Additionally, its Average True Range was 0.15.
During the past 100 days, Editas Medicine Inc’s (EDIT) raw stochastic average was set at 0.00%, which indicates a significant increase from 0.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 71.76% in the past 14 days, which was lower than the 81.96% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.0786, while its 200-day Moving Average is $4.1061. Nevertheless, the first resistance level for the watch stands at $1.2133 in the near term. At $1.2667, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.2933. If the price goes on to break the first support level at $1.1333, it is likely to go to the next support level at $1.1067. Assuming the price breaks the second support level, the third support level stands at $1.0533.
Editas Medicine Inc (NASDAQ: EDIT) Key Stats
There are 82,548K outstanding shares of the company, which has a market capitalization of 95.76 million. As of now, sales total 78,120 K while income totals -153,220 K. Its latest quarter income was 60 K while its last quarter net income were -62,140 K.
